Mineralocorticoid receptor antagonist use in eligible patients following acute myocardial infarction: Real world data from the Acute Coronary Syndrome Israeli Surveys: 2004-2010

International Journal of Cardiology

Volumn 168, Issue 4, 2013, Pages 3971-3976

  Koifman, Edward ^a,b   Kopel, Eran ^a,b   Maor, Elad ^a,b   Fefer, Paul ^a,b   Matezky, Shlomi ^a,b   Tofler, Goeffrey ^c   Hamdan, Ashraf ^a,b   Grossman, Ehud ^b   Goldenberg, Ilan ^a,b   Klempfner, Robert ^a,b  

^a Chaim Sheba   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Acute myocardial infarction; Heart failure; Mineralocorticoid receptor antagonist

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MINERALOCORTICOID ANTAGONIST;

ACUTE HEART INFARCTION; AGED; ARTICLE; DRUG UTILIZATION; FEMALE; FOLLOW UP; HEALTH SURVEY; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; ISRAEL; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; ACUTE CORONARY SYNDROME; EPIDEMIOLOGY; FACTUAL DATABASE; MIDDLE AGED; PROSPECTIVE STUDY; REGISTER; TREATMENT OUTCOME; TRENDS; VERY ELDERLY;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HEALTH SURVEYS; HUMANS; ISRAEL; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; PATIENT DISCHARGE; PROSPECTIVE STUDIES; REGISTRIES; TREATMENT OUTCOME;

EID: 84886260781     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.06.091     Document Type: Article

References (38)

1. B. Pitt, F. Zannad, and W.J. Remme The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators N Engl J Med 341 1999 709 717
2. F. Zannad, J.J. McMurray, and H. Krum Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 2011 11 21
3. S.A. Hunt, W.T. Abraham, and M.H. Chin Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in collaboration with the International Society for Heart and Lung Transplantation J Am Coll Cardiol 53 2009 e1 e90
4. J.J. McMurray, S. Adamopoulos, and S.D. Anker ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC Eur Heart J 33 2012 1787 1847
5. B. Pitt, W. Remme, and F. Zannad Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 2003 1309 1321
6. E.M. Antman, D.T. Anbe, and P.W. Armstrong ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction) J Am Coll Cardiol 44 2004 E1 E211
7. J.L. Anderson, C.D. Adams, and E.M. Antman ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine Circulation 116 2007 e148 e304
8. J.P. Bassand, C.W. Hamm, and D. Ardissino Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes Eur Heart J 28 2007 1598 1660
9. F. Van de Werf, J. Bax, and A. Betriu Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology Eur Heart J 29 2008 2909 2945
10. N.M. Albert, C.W. Yancy, and L. Liang Use of aldosterone antagonists in heart failure JAMA 302 2009 1658 1665
11. G.C. Fonarow, N.M. Albert, and A.B. Curtis Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF) Circulation 122 2010 585 596
12. A.N. Rassi, M.A. Cavender, and G.C. Fonarow Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction J Am Coll Cardiol 61 2013 35 40
13. S. Behar, A. Battler, and A. Porath A prospective national survey of management and clinical outcome of acute myocardial infarction in Israel, 2000 Isr Med Assoc J 5 2003 249 254
14. A.P. Maggioni, U. Dahlstrom, and G. Filippatos EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot) Eur J Heart Fail 12 2010 1076 1084
15. S. Hamaguchi, S. Kinugawa, and M. Tsuchihashi-Makaya Spironolactone use at discharge was associated with improved survival in hospitalized patients with systolic heart failure Am Heart J 160 2010 1156 1162
16. J.G. Cleland, A. Cohen-Solal, and J.C. Aguilar Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey Lancet 360 2002 1631 1639
17. M. Komajda, F. Follath, and K. Swedberg The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment Eur Heart J 24 2003 464 474
18. F.A. Masoudi, C.P. Gross, and Y. Wang Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001 Circulation 112 2005 39 47
19. P. de Groote, R. Isnard, and P. Clerson Improvement in the management of chronic heart failure since the publication of the updated guidelines of the European Society of Cardiology. The Impact-Reco Programme Eur J Heart Fail 11 2009 85 91
20. K. Dickstein, A. Cohen-Solal, and G. Filippatos ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur Heart J 29 2008 2388 2442
21. M. Lainscak, J.G. Cleland, M.J. Lenzen, F. Follath, M. Komajda, and K. Swedberg International variations in the treatment and co-morbidity of left ventricular systolic dysfunction: data from the EuroHeart Failure Survey Eur J Heart Fail 9 2007 292 299
22. E. Lopez-de-Sa, A. Martinez, M. Anguita, D. Dobarro, and M. Jimenez-Navarro Aldosterone receptor antagonist use after myocardial infarction. Data from the REICIAM registry Rev Esp Cardiol 64 2011 981 987
23. B. Pitt, G. Bakris, L.M. Ruilope, L. DiCarlo, R. Mukherjee, and E. Investigators Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) Circulation 118 2008 1643 1650
24. K.P. Tamirisa, K.D. Aaronson, and T.M. Koelling Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure Am Heart J 148 2004 971 978
25. D.N. Juurlink, M.M. Mamdani, and D.S. Lee Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study N Engl J Med 351 2004 543 551
26. B. Bozkurt, I. Agoston, and A.A. Knowlton Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines J Am Coll Cardiol 41 2003 211 214
27. K.B. Shah, K. Rao, R. Sawyer, and S.S. Gottlieb The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure J Am Coll Cardiol 46 2005 845 849
28. J. Butler, J.A. Ezekowitz, and S.P. Collins Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction heart failure Society of America guidelines committee J Card Fail 18 2012 265 281
29. L. Wei, A.D. Struthers, T. Fahey, A.D. Watson, and T.M. Macdonald Spironolactone use and renal toxicity: population based longitudinal analysis BMJ 340 2010 c1768
30. G. Chernin, A. Gal-Oz, and E. Ben-Assa Secondary prevention of hyperkalemia with sodium polystyrene sulfonate in cardiac and kidney patients on renin-angiotensin-aldosterone system inhibition therapy Clin Cardiol 35 2012 32 36
31. B. Pitt, S.D. Anker, D.A. Bushinsky, D.W. Kitzman, F. Zannad, and I.Z. Huang Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial Eur Heart J 32 2011 820 828
32. H.M. Krumholz, J.L. Anderson, and B.L. Bachelder ACC/AHA 2008 performance measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on performance measures (writing committee to develop performance measures for ST-elevation and non-ST-elevation myocardial infarction): developed in collaboration with the American Academy of Family Physicians and the American College of Emergency Physicians: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation, Society for Cardiovascular Angiography and Interventions, and Society of Hospital Medicine Circulation 118 2008 2596 2648
33. B. Pitt, H. White, and J. Nicolau Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure J Am Coll Cardiol 46 2005 425 431
34. C. Adamopoulos, A. Ahmed, and R. Fay Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial Eur J Heart Fail 11 2009 1099 1105
35. M. Hayashi, T. Tsutamoto, and A. Wada Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction Circulation 107 2003 2559 2565
36. C.W. Hamm, J.P. Bassand, and S. Agewall ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the Management of Acute Coronary Syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J 32 2011 2999 3054
37. P.G. Steg, S.K. James, and D. Atar ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology (ESC) Euro Heart J 33 2012 2569 2619
38. P.T. O'Gara, F.G. Kushner, and D.D. Ascheim 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines J Am Coll Cardiol 61 2013 e78 e140